Explore the words cloud of the Fingers4Cure project. It provides you a very rough idea of what is the project "Fingers4Cure" about.
The following table provides information about the project.
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
|Coordinator Country||United Kingdom [UK]|
|Total cost||149˙995 €|
|EC max contribution||149˙995 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2015-02-01 to 2016-07-31|
Take a look of project's partnership.
|1||IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE||UK (LONDON)||coordinator||149˙995.00|
Huntington’s disease (HD) is a lethal inherited neurodegenerative disorder which currently has no cure. Patients develop a devastating loss of muscle control and brain function, with symptoms typically developing at 35 - 45 years of age, although they can start much earlier. Suffering is high for both patients and carers, with death generally occurring within 10 - 15 years of diagnosis. We are working on a novel, curative gene therapy approach based on reducing the levels of the HTT disease gene products, while maintaining the levels of the normal protein. It is based on the delivery of proprietary zinc finger proteins (ZFPs) to the brain. Efficient delivery is accomplished through the use of viral vectors that carry the sequences coding for our ZFPs. Such ZFPs are artificially engineered proteins that specifically bind the defective expanded HTT DNA sequences (but not the normal HTT sequences or other, unrelated sequences). Binding represses the synthesis of the toxic gene products. We have published data demonstrating efficient mutant HTT repression in mouse (Garriga-Canut, M., et al. & Isalan M. Synthetic zinc finger repressors reduce mutant Huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109: E3136-E3145, 2012). We now need to improve the viral vectors for the long term expression of our ZFPs in the mouse brain, as the basis for a single-intervention, long-term therapy in humans (technical improvements). In parallel, we need to maintain the patent applications that protect the technology through various national and regional phases, and protect new developments that may arise (intellectual property), while engaging the necessary IPR and market studies/activities that help us find an industry partner that licenses our technology and moves it forward into the clinic (exploitation). This proof of concept grant is critical in all three aspects.
|year||authors and title||journal||last update|
Michal Mielcarek, Mark Isalan
A shared mechanism of muscle wasting in cancer and Huntingtonâ€™s disease
published pages: , ISSN: 2001-1326, DOI: 10.1186/s40169-015-0076-z
|Clinical and Translational Medicine 4/1||2019-07-23|
Carmen AgustÃn-PavÃ³n, Michal Mielcarek, Mireia Garriga-Canut, Mark Isalan
Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice
published pages: , ISSN: 1750-1326, DOI: 10.1186/s13024-016-0128-x
|Molecular Neurodegeneration 11/1||2019-07-23|
Huntington\'s disease is a multi-system disorder
published pages: e1058464, ISSN: 2167-5511, DOI: 10.1080/21675511.2015.1058464
|Rare Diseases 3/1||2019-07-23|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FINGERS4CURE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FINGERS4CURE" are provided by the European Opendata Portal: CORDIS opendata.